CSIMarket
 
Cellectar Biosciences inc   (CLRB)
Other Ticker:  
 
 
Price: $3.3500 $-0.13 -3.736%
Day's High: $3.51 Week Perf: -7.71 %
Day's Low: $ 3.35 30 Day Perf: -6.69 %
Volume (M): 472 52 Wk High: $ 4.45
Volume (M$): $ 1,580 52 Wk Avg: $2.33
Open: $3.51 52 Wk Low: $1.30



 Market Capitalization (Millions $) 38
 Shares Outstanding (Millions) 11
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -35
 Cash Flow (TTM) (Millions $) 1
 Capital Exp. (TTM) (Millions $) 1

Cellectar Biosciences Inc
Cellectar Biosciences Inc. is a clinical-stage biopharmaceutical company that develops targeted drugs for the treatment of cancer. The company primarily focuses on developing novel phospholipid drug conjugates (PDCs), which deliver potent therapeutic agents selectively to cancer cells. Cellectar's PDC platform has the potential to improve the efficacy and safety of current cancer treatments by increasing tumor targeting while reducing damage to healthy cells.

Cellectar's lead product candidate, CLR 131, is being evaluated in multiple Phase 2 clinical trials for various types of cancer, including multiple myeloma, lymphoma, and pediatric solid tumors. CLR 131 targets cancer cells by binding to specific receptors on their surface and delivers a radioactive isotope directly to the tumor, resulting in targeted killing of cancer cells.

In addition to CLR 131, Cellectar has a robust pipeline of other PDC candidates in preclinical development, targeting different types of cancer. The company continues to invest in research and development to expand its product portfolio and explore the potential applications of its innovative technology.

Overall, Cellectar Biosciences Inc. is dedicated to developing targeted therapies that can significantly improve the outcomes and quality of life for cancer patients.


   Company Address: 100 Campus Drive Florham Park 7932 NJ
   Company Phone Number: 441-8120   Stock Exchange / Ticker: NASDAQ CLRB
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Breaking New Ground: Iopofosine Combination Therapy Shows Promise in Recurrent Head and Neck Cancer Treatment.

Published Mon, Mar 4 2024 11:40 AM UTC

In a recent press release, Cellectar Biosciences, a renowned biopharmaceutical company, announced positive findings from an investigator-initiated Phase 1 study evaluating the safety and efficacy of Iopofosine in combination with external beam radiotherapy (EBRT) for the treatment of recurrent head and neck cancer. This groundbreaking research brings new hope to patients and...

Clinical Study

Cellectar Biosciences Kickstarts Enrollment in Pediatric Gliomas Clinical Study Backed by NCI's $2 Million Grant

Published Tue, Jan 30 2024 11:40 AM UTC

Cellectar Biosciences has begun enlisting participants for its Phase 1b clinical study focusing on pediatric high-grade gliomas, a significant milestone in oncological research. The U.S. clinical-stage biopharmaceuticals company, notable for pursuing novel therapeutic solutions in cancer, announced that the first patient enrollment has occurred. The research involves the uti...

Shares

Cellectar Biosciences Experiences Successful Tranche A Warrant Exercise, Garnering $44.1 Million in Proceeds

Published Thu, Jan 25 2024 11:40 AM UTC


FLORHAM PARK, N.J., Jan. 25, 2024 - Cellectar Biosciences, Inc. (NASDAQ: CLRB), a renowned late-stage clinical biopharmaceutical company specializing in the research, development, and commercialization of innovative cancer treatments, made a significant announcement today. The Tranche A warrants, which were issued as part of a private placement back in September 2023, h...

Clinical Study

Cellectar Biosciences Revolutionizes Cancer Therapy with Targeted Alpha Therapy for Solid Tumors: Promising Preclinical Data Shows Effectiveness against Resistant Pancreatic Cancer

Published Tue, Jan 16 2024 11:40 AM UTC

Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical DataIn a recent press release, Cellectar Biosciences, a clinical-stage biopharmaceutical company, announced significant advancements in its pipeline with the development of Targeted Alpha Therapy (TAT) for the treatment of solid tumors. The company al...

Partnership

Revolutionizing Waldenstrom's Macroglobulinemia Treatment: Cellectar Biosciences Collaborates with MiBA, an American Oncology Network Data Subsidiary.

Published Thu, Jan 11 2024 11:40 AM UTC

Cellectar Biosciences, a leading clinical-stage biopharmaceutical company focusing on the discovery, development, and commercialization of innovatively prepared drugs for cancer treatment, has declared their alliance with MiBA, a data subsidiary of the American Oncology Network. This partnership aims at promoting the advanced treatment of Waldenstrom's Macroglobulinemia (WM)...






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com